Enduring Material

20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
Temple Health

7600 Central Avenue
Philadelphia, PA 19111
General Information
Monday, February 7, 2022 - Saturday, December 31, 2022
Fox Chase Cancer Center
Virtual Conference Room
20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium
Temple Health
Objectives
  • Analyze the advances in the management of breast cancer and premalignant breast disease and, when clinically relevant, integrate new findings into the management of patients with breast cancer and premalignant breast disease.
  • When clinically relevant, apply new strategies for optimizing existing treatments into the management of these patients.
  • Analyze new developments in breast cancer research and current available clinical trials and when clinically relevant, include this information in discussions with patients.
Presentations and Speakers
TNBC and Immunotherapy - No Credit
  • Elias Obeid, MD
Available Credits/Points
  • Temple Health designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statements
Lori J Goldstein, MD, Program Director, has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Daiichi Sankyo - DSMB - Relationship Has Not Ended
• Genentech - Advisory Committee Member - Relationship Ended
• Eisai - Advisory Committee Member - Relationship Has Not Ended
• Astra Zeneca - Advisory Committee Member - Relationship Ended
• Merck - Advisory Committee Member - Relationship Has Not Ended
• Exact Sciences - Advisory Committee Member - Relationship Ended
• Immunomedics - Advisory Committee Member - Relationship Ended
• Biovica Divitum - Advisory Committee Member - Relationship Ended

All relevant financial relationships with ineligible companies have been mitigated.
Speakers:
Elias Obeid, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Merck - Contracted Research - Relationship Has Not Ended
  • Genentech - Contracted Research - Relationship Has Not Ended
  • GSK - Advisory Committee Member - Relationship Ended
  • Pfizer - Advisory Committee Member - Relationship Ended
  • Pfizer - Speakers Bureau - Relationship Ended
  • Pfizer - Consulting - Relationship Has Not Ended
  • Astra Zeneca - Steering committee - Relationship Has Not Ended
All of the relevant financial relationships listed for these individuals have been mitigated.

Planners and other Administrative Support:
Lori J Goldstein, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Daiichi Sankyo - DSMB - Relationship Has Not Ended
  • Genentech - Advisory Committee Member - Relationship Ended
  • Eisai - Advisory Committee Member - Relationship Has Not Ended
  • Astra Zenica - Advisory Committee Member - Relationship Ended
  • MERCK - Advisory Committee Member - Relationship Has Not Ended
  • Exact Sciences - Advisory Committee Member - Relationship Ended
  • Immunomedics - Advisory Committee Member - Relationship Ended
  • Biovica Divitum - Advisory Committee Member - Relationship Ended
All of the relevant financial relationships listed for these individuals have been mitigated.

This activity is not commercially supported.
Test Information
100 %
3/14/2022
Continue to Enduring Material